AstraZeneca's Enhertu (Trastuzumab Deruxtecan) Demonstrated Clinically Meaningful Progression-Free Survival, Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca's Enhertu (Trastuzumab Deruxtecan) has shown clinically meaningful progression-free survival and overall survival across multiple HER2 expressing advanced solid tumors in the DESTINY-PanTumor02 Phase 2 trial.
July 27, 2023 | 8:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Enhertu has demonstrated positive results in a Phase 2 trial, which could potentially lead to increased demand for the drug and positive impact on the company's stock.
The positive results from the Phase 2 trial of Enhertu indicate a potential increase in demand for the drug, which could lead to increased revenues for AstraZeneca. This could have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100